CytomX Expands Executive Leadership Team

SOUTH SAN FRANCISCO, Calif., May 27, 2015 /PRNewswire/ -- CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the appointments of Bob Goeltz as chief financial officer and Cynthia Ladd as senior vice president and general counsel. Prior to joining CytomX, Goeltz was chief financial officer of Onyx Pharmaceuticals, an Amgen subsidiary. Ms. Ladd previously served as an independent consultant and legal counsel to several leading biotech companies, including CytomX.

"CytomX continues to execute towards building a long-term, multi-product company, and I am thrilled to be further strengthening our senior team with the additions of Bob and Cynthia," said Sean McCarthy, D.Phil, chief executive officer of CytomX. "Bob brings broad-based financial and operating experience to guide our future financing activities as we focus on long term value creation. Cynthia has been a trusted business advisor to the company through its growth and now will join us in a permanent position."

During his 11 year tenure at Amgen, Mr. Goeltz held numerous positions in finance. He played an integral role in Amgen's $10.4 billion acquisition of Onyx and worked with leadership to deliver financial performance across multiple oncology therapeutics, including recently launched Blincyto™. Earlier in his career, he served as director of finance for Tularik. In this position, he supported the raise of more than $100 million in follow-on offerings. Mr. Goeltz began his career as an audit manager for Ernst & Young where he supported a number of initial public offerings. He received his master's in business administration from the University of California Los Angeles' Anderson School of Management and his bachelor's degree from Emory University's Goizueta Business School.

Ms. Ladd most recently was an independent consultant to biotechnology companies, supporting corporate growth by advising on corporate strategy, negotiations around collaborations, and clinical and regulatory issues, as well as acting as general counsel. Before this, she was president and chief executive officer of AGY Therapeutics. During her tenure, she guided the company through a successful venture round and its transition to a clinical organization. Ms. Ladd previously served as senior vice president and general counsel at Pharmacyclics. In this role, she led various operating groups, including Regulatory Affairs, advised on corporate governance and compliance matters, structured negotiations for business development activities and led all of the legal activities at the company, including those related to the company's intellectual property portfolio. Earlier in her career, Ms. Ladd held a number of positions at Genentech, including vice president of corporate law and chief corporate counsel. She began her career as an associate with Wilson, Sonsini, Goodrich & Rosati and Ware & Freidenrich (now DLA Piper). Ms. Ladd received her law degree from Stanford Law School, a master's degree in animal nutrition and biochemistry from Cornell University and a bachelor's degree in animal science from Pennsylvania State University.

About CytomX Therapeutics
CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. CytomX has attracted multiple strategic collaborations with industry-leading pharmaceutical companies including Pfizer Inc., ImmunoGen and Bristol-Myers Squibb. CytomX is led by a seasoned and proven management team and is financed by leading life science investors, including Third Rock Ventures, Canaan Partners, Roche Venture Fund and Pfizer Venture Investments. For more information, please visit www.cytomx.com.

Media Contacts:
Canale Communications
Ian Stone
[email protected]
619-849-5388

SOURCE CytomX Therapeutics

Related Links

http://www.cytomx.com